Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
复制标题
DOI：
10.1136/bjophthalmol-2014-305327
复制
发表时间：
2015-02-01
影响因子：
4.1
通讯作者：
Sivaprasad, Sobha
中科院分区：
文献类型：
--
作者：
Holz, Frank G.;Tadayoni, Ramin;Sivaprasad, Sobha
背景/目的在加拿大、法国、德国、爱尔兰、意大利、荷兰、英国和委内瑞拉进行的一项回顾性观察性研究中，对湿性老年性黄斑变性(WAMD)患者的抗血管内皮生长因子(VEGF)治疗进行了评估。数据收集至治疗和/或监测结束或至2011年8月31日。结果2227例接受>；=1抗血管内皮生长因子注射的患者接受了基线视力评估和>；=1基础视力评估。视力提高到第120天左右；此后，视力增长不再保持。从基线到第一年和第二年视力评分的平均变化分别为+2.4和+0.6个字母。患者在第一年和第二年分别接受了平均5.0次和2.2次注射。不同国家之间的视觉结果和注射频率有很大差异。更频繁的就诊和注射与视力的改善有关。结论在临床实践中，注射比临床试验中使用的更少。抗血管内皮生长因子治疗最初导致了视力的改善；然而，这种情况并没有随着时间的推移而保持。
Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela.Methods Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011.Results 2227 patients who received >= 1 anti-VEGF injection with a baseline visual acuity assessment and >= 1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity.Conclusions In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time.